In this episode, Joe interviews Nick Kadysh: Founder and CEO of PharmAla Biotech and member of the board of directors for The Canadian Psychedelic Businesses Association.  PharmAla Biotech is a Toronto-based Life Sciences company with two focuses: contracting with manufacturers to provide researchers with GMP MDMA (created under Good Manufacturing Practice regulations), and creating and […]

The post PT410 – Manufacturing MDMA and Why Creating MDMA Analogs Is So Important appeared first on Psychedelics Today.

Previous articleatai Life Sciences Presents Pharmacodynamic Data on GRX-917 in a Late Breaking Poster Presentation at the 2023 SOBP Annual Meeting
Next articleOptimi Health Completes Harvest Of Psilocybe Cubensis For Delivery To The Australian Medical Market